Back

Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists

Nilson, A. N.; Felsing, D. E.; Wang, P.; Jain, M.; Zhou, J.; Allen, J.

2024-04-17 pharmacology and toxicology
10.1101/2024.04.15.589637 bioRxiv
Show abstract

The dopamine D1 receptor (D1R) has fundamental roles in voluntary movement and memory and is a validated drug target for neurodegenerative and neuropsychiatric disorders. However, previously developed D1R selective agonists possess a catechol moiety which displays poor pharmacokinetic properties. The first selective non-catechol D1R agonists were recently discovered and unexpectedly many of these ligands showed G protein biased signaling. Here, we investigate both catechol and non-catechol D1R agonists to validate potential biased signaling and examine if this impacts agonist-induced D1R endocytosis. We determined that most, but not all, non-catechol agonists display G protein biased signaling at the D1R and have reduced or absent {beta}-arrestin recruitment. A notable exception was compound (Cmpd) 19, a non-catechol agonist with full efficacy at both D1R-G protein or D1R-{beta}-arrestin pathways. In addition, the catechol ligand A-77636 was a highly potent, super agonist for D1R-{beta}-arrestin activity. When examined for agonist-induced D1R endocytosis, balanced agonists SKF-81297 and Cmpd 19 induced robust D1R endocytosis while the G protein biased agonists did not. The {beta}-arrestin super agonist, A-77636, showed significantly increased D1R endocytosis. Moreover, {beta}-arrestin recruitment efficacy of tested agonists strongly correlated with total D1R endocytosis. Taken together, these results indicate the degree of D1R signaling functional selectivity profoundly impacts D1R endocytosis regardless of pharmacophore. The range of functional selectivity of these D1R agonists will provide valuable tools to further investigate D1R signaling, trafficking and therapeutic potential. Significance StatementThe D1R is a validated therapeutic target and the recently discovered non-catechol D1R agonists have translational potential. We have systematically characterized several structurally distinct D1R agonists including non-catechols with balanced or G protein biased activity. When examined for agonist-induced D1R endocytosis, balanced agonists induced robust D1R endocytosis while G protein biased agonists did not. These results indicate the degree of D1R signaling functional selectivity profoundly impacts receptor endocytosis. This work also independently validates agonist tools to further investigate D1R activation in basic and translational research.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
23.0%
2
Frontiers in Pharmacology
100 papers in training set
Top 0.1%
19.0%
3
Scientific Reports
3102 papers in training set
Top 22%
4.9%
4
British Journal of Pharmacology
34 papers in training set
Top 0.1%
4.9%
50% of probability mass above
5
Neuropharmacology
60 papers in training set
Top 0.2%
3.7%
6
Molecular Pharmacology
15 papers in training set
Top 0.1%
3.7%
7
ACS Chemical Neuroscience
60 papers in training set
Top 0.7%
2.8%
8
PLOS ONE
4510 papers in training set
Top 45%
2.7%
9
Pharmacology Research & Perspectives
11 papers in training set
Top 0.1%
2.1%
10
Neuropsychopharmacology
134 papers in training set
Top 1%
2.1%
11
eLife
5422 papers in training set
Top 35%
2.1%
12
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
1.9%
13
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 29%
1.9%
14
Psychopharmacology
59 papers in training set
Top 0.4%
1.7%
15
Molecular Psychiatry
242 papers in training set
Top 2%
1.5%
16
Nature Communications
4913 papers in training set
Top 56%
1.2%
17
Journal of Medicinal Chemistry
68 papers in training set
Top 0.8%
1.2%
18
Neurotherapeutics
11 papers in training set
Top 0.5%
0.8%
19
Biological Psychiatry Global Open Science
54 papers in training set
Top 1%
0.8%
20
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.7%
0.8%
21
Translational Psychiatry
219 papers in training set
Top 4%
0.7%
22
Molecular Pharmaceutics
16 papers in training set
Top 0.6%
0.7%
23
iScience
1063 papers in training set
Top 36%
0.7%
24
Addiction Biology
47 papers in training set
Top 0.8%
0.5%
25
Journal of Neuroendocrinology
19 papers in training set
Top 0.5%
0.5%
26
Journal of the American Chemical Society
199 papers in training set
Top 6%
0.5%
27
Diabetes
53 papers in training set
Top 0.8%
0.5%
28
Cell Chemical Biology
81 papers in training set
Top 5%
0.5%
29
PLOS Genetics
756 papers in training set
Top 18%
0.5%
30
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.4%
0.5%